Cellectar Biosciences Company Insiders
CLRB Stock | USD 5.20 0.03 0.57% |
Cellectar Biosciences employs about 11 people. The company is managed by 7 executives with a total tenure of roughly 18 years, averaging almost 2.0 years of service per executive, having 1.57 employees per reported executive. Analysis of Cellectar Biosciences' management performance can provide insight into the company performance.
James Caruso CEO CEO and President and Director |
Jarrod Longcor President Senior Vice President - Corporate Development and Operations |
Cellectar | Build AI portfolio with Cellectar Stock |
Cellectar Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.9792) % which means that it has lost $0.9792 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0872) %, meaning that it created substantial loss on money invested by shareholders. Cellectar Biosciences' management efficiency ratios could be used to measure how well Cellectar Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Cellectar Biosciences Workforce Comparison
Cellectar Biosciences is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 645. Cellectar Biosciences claims roughly 11.0 in number of employees contributing just under 2% to equities under Health Care industry.
Cellectar Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cellectar Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cellectar Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cellectar Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hill Stephen A over three months ago Acquisition by Hill Stephen A of 50000 shares of Cellectar Biosciences at 1.28 subject to Rule 16b-3 | ||
Kolean Chad J over three months ago Disposition of tradable shares by Kolean Chad J of Cellectar Biosciences subject to Rule 16b-3 | ||
Darrell Lea over three months ago Acquisition by Darrell Lea of 100000 shares of Cellectar Biosciences at 1.68 subject to Rule 16b-3 | ||
Swirsky Douglas J over three months ago Acquisition by Swirsky Douglas J of 90000 shares of Cellectar Biosciences at 0.29 subject to Rule 16b-3 | ||
James Caruso over three months ago Acquisition by James Caruso of 900000 shares of Cellectar Biosciences at 2.65 subject to Rule 16b-3 | ||
Chanan-khan Asher over six months ago Insider Trading | ||
Chanan-khan Asher over six months ago Insider Trading | ||
Jarrod Longcor over six months ago Acquisition by Jarrod Longcor of 450000 shares of Cellectar Biosciences at 1.74 subject to Rule 16b-3 |
Cellectar Biosciences Notable Stakeholders
A Cellectar Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cellectar Biosciences often face trade-offs trying to please all of them. Cellectar Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cellectar Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
James Caruso | CEO and President and Director | Profile | |
Jarrod Longcor | Senior Vice President - Corporate Development and Operations | Profile | |
Chad CPA | CFO VP | Profile | |
CPA CPA | CFO Sec | Profile | |
Andrei MD | Senior Medical | Profile | |
Shane Lea | Chief Officer | Profile | |
Darrell Lea | Chief Officer | Profile |
About Cellectar Biosciences Management Performance
The success or failure of an entity such as Cellectar Biosciences often depends on how effective the management is. Cellectar Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cellectar management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cellectar management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. Cellectar Biosc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.
Please note, the presentation of Cellectar Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cellectar Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cellectar Biosciences' management manipulating its earnings.
Cellectar Biosciences Workforce Analysis
Traditionally, organizations such as Cellectar Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cellectar Biosciences within its industry.Cellectar Biosciences Manpower Efficiency
Return on Cellectar Biosciences Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 4.1M | |
Net Loss Per Executive | 6.4M | |
Working Capital Per Employee | 1.4M | |
Working Capital Per Executive | 2.1M |
Complementary Tools for Cellectar Stock analysis
When running Cellectar Biosciences' price analysis, check to measure Cellectar Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectar Biosciences is operating at the current time. Most of Cellectar Biosciences' value examination focuses on studying past and present price action to predict the probability of Cellectar Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectar Biosciences' price. Additionally, you may evaluate how the addition of Cellectar Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |